Hamburg ots - Ein Pressesprecher verdient in Deutschland im Durchschnitt monatlich 4. Reducing the number of bleeding episodes is a key consideration as they are very painful and frightening for patients Turoctocog fdating caregivers and can lead to severe long-term joint damage or
Turoctocog fdating. NovoEight R has been carefully designed using advanced protein and purification
Turoctocog fdating to provide a reliable and portable treatment option Turoctocog fdating people with haemophilia A combined with a good safety profile.
TM 2 is the extension of the pivotal guardian TM Turoctocog fdating programme, one of the largest and most comprehensive pre-registration clinical trial programmes Turoctocog fdating haemophilia, with more than severe haemophilia A patients treated.
Guardian TM 2 is an open-label, multinational, single-arm extension trial involving haemophilia A patients from 18 countries had been previously enrolled in the guardian TM 1 and guardian TM 3 trials. Patients received NovoEight R in a preventative regimen and to treat breakthrough bleeds.
NovoEight R has also been approved in Japan and Australia Turoctocog fdating and in Switzerland February and applications for regulatory approvals have been submitted in a range of other countries. In addition to NovoEight RNovo Nordisk has developed a
Turoctocog fdating portfolio of molecules aimed at improving haemophilia treatment.
Turoctocog fdating in the clinical development pipeline include N8-GP, designed to provide a longer half-life Turoctocog fdating the potential to reduce the treatment burden for people with haemophilia A and N9-GP, Turoctocog fdating long-acting recombinant factor IX for haemophilia B that has the potential to significantly reduce bleeding with weekly injections. Haemophilia is a chronic, inherited bleeding disorder that primarily affects males.
People with haemophilia A are either missing or have a malfunctioning factor VIII protein, which is essential for proper blood
Turoctocog fdating. People with haemophilia A have a tendency to bleed longer than most, or to bleed internally into muscles, joints or organs, because they are this clotting factor.
To manage the disease and stop bleeding, people with haemophilia A must replace
Turoctocog fdating factor VIII protein, which is accomplished by intravenous injection of the clotting factor.
Globally, it is estimated thatpeople have haemophilia. Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care.
The company also has leading positions within haemophilia care, growth hormone therapy and hormone-replacement therapy.
Novo Nordisk Turoctocog fdating approximately 40, employees in 75 countries, and its products in more than countries. For more information, visit novonordisk. Novo Nordisk in Haemophilia In addition to NovoEight RNovo Nordisk has developed a comprehensive portfolio of molecules aimed at improving haemophilia treatment. About Haemophilia A Haemophilia is a chronic, inherited bleeding disorder that primarily affects males. References 1 Ozelo M.
Lowering in annualized bleeding rates over time with turoctocog alfa prophylaxis: Results from a
Turoctocog fdating multinational clinical trial guardian TM 1 using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: Results from a large multinational clinical trial guardian TM 3 using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: To view the Multimedia Novo Nordisk today Turoctocog fdating a unique partnership to form Team Novo Nordisk, a global sports team with more than cyclists, triathletes Turoctocog fdating runners who all have diabetes, spearheaded by the world's first all-diabetes pro-cycling team.
view the Multimedia News
Turoctocog fdating fdating, please click: